Kawai M, Momoi T, Yorifuji T, Yamanaka C, Sasaki H, Furusho K
Department of Pediatrics, Faculty of Medicine, Kyoto University, Japan.
J Pediatr. 1997 Feb;130(2):205-9. doi: 10.1016/s0022-3476(97)70344-5.
A group of 18 boys with non-growth hormone (GH)-deficient short stature without GH therapy (group A) and another group of 9 boys with non-GH-deficient short stature with GH therapy in doses of 0.5 IU (0.17 mg)/kg per week administered 5 to 6 times weekly (group B) were observed until they reached their final height. The mean duration of GH therapy was 4.2 years (range 3.2 to 5.0 years). These two groups were matched with respect to their standard deviation score (SDS) for bone age at the start of observation. Mean +/- SD of the final height for group A and group B was 162.0 +/- 5.4 cm and 154.2 +/- 4.2 cm, respectively. During the prepubertal period, height SDS for bone age of these two groups was not affected by GH therapy. During the pubertal period, however, height SDS for bone age remained constant for group A but decreased gradually for group B. Our observation indicates that for boys with non-GH-deficient short stature GH therapy does not improve height SDS for bone age during the prepubertal period, and in fact reduces it during the pubertal period, possibly resulting in a shorter final height than might have been attained naturally.
观察了一组18名未接受生长激素（GH）治疗的非生长激素缺乏性身材矮小男孩（A组）和另一组9名接受生长激素治疗的非生长激素缺乏性身材矮小男孩（B组），B组每周接受0.5 IU（0.17 mg）/kg剂量的生长激素治疗，每周给药5至6次，直至他们达到最终身高。生长激素治疗的平均持续时间为4.2年（范围3.2至5.0年）。这两组在观察开始时骨龄的标准差评分（SDS）方面相匹配。A组和B组的最终身高平均值±标准差分别为162.0±5.4厘米和154.2±4.2厘米。在青春期前阶段，这两组的骨龄身高SDS不受生长激素治疗的影响。然而，在青春期期间，A组的骨龄身高SDS保持不变，而B组则逐渐下降。我们的观察表明，对于非生长激素缺乏性身材矮小的男孩，生长激素治疗在青春期前阶段不会改善骨龄身高SDS，而实际上在青春期会降低该指标，这可能导致最终身高比自然生长可能达到的身高更矮。
